Dr. Reddy's Lab to acquire portfolio of 42 ANDAs in US

15 Apr 2019 Evaluate

Dr. Reddy's Laboratories has entered into a definitive agreement to acquire a portfolio of 42 approved, non-marketed Abbreviated New Drug Applications (ANDAs) in the US. The portfolio includes more than 30 generic injectable products. These products will require to be technology transferred and could be launched within the next one to two years.

The value of total addressable market for these products in the US is approximately $645 million for the calendar year ending in December 2018 according to IQVIA.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1270.25 -8.75 (-0.68%)
17-Dec-2025 13:37 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1793.40
Dr. Reddys Lab 1270.25
Cipla 1495.20
Zydus Lifesciences 918.00
Lupin 2108.70
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×